摘要
目的探讨胸腔注射尿激酶联合地塞米松治疗结核性胸膜炎的疗效与安全性。方法选取2009年4月～2012年6月浙江省温岭市第四人民医院收治的126例结核性胸膜炎患者,将其随机分为A、B、C三组,每组42例。所有患者均通过胸腔给药,A组患者接受尿激酶,B组患者接受地塞米松,C组患者接受尿激酶联合地塞米松。结果 A、B、C三组的胸腔积液消失时间、胸膜厚度、胸膜粘连率分别为:A组:(17.4±3.5)d,(1.92±0.35)mm,26.2%;B组:(17.0±3.7)d,(1.87±0.39)mm,31.0%;C组:(13.5±2.9)d,(1.32±0.29)mm,7.1%。三组患者胸腔积液消失时间、胸膜厚度、胸膜粘连率相比差异有统计学意义(P<0.05),C组患者胸腔积液消失时间显著短于A组与B组(P<0.05),胸膜厚度显著薄于A组与B组(P<0.05),胸膜粘连率显著低于A组与B组(P<0.05)。三组患者不良反应发生率相比差异无统计学意义(P>0.05)。结论胸腔注射尿激酶联合地塞米松是治疗结核性胸膜炎的有效方案之一,值得临床应用与推广。
Objective To investigate the efficacy and safety of the treatment of tuberculous pleurisy of intrapleural in jection of Urokinase combined with Dexamethasone.Methods 126 cases of patients with tuberculous pleurisy from April 2009 to June 2012 in the Fourth People＇s Hospital of Wenling City were randomly divided into group A,B,C,each group containing 42 patients,all patients were treated through chest,group A received Urokinase,group B re ceived Dexamethasone,group C received Urokinase and Dexamethasone.Results The pleural effusion,pleural thickness,the disappearing time of pleural adhesion rate of group A,B,C was respectively： group A：（17.4 ±3.5） d,（1.92±0.35） mm,26.2%;group B：（17.0±3.7） d,（1.87±0.39） mm,31.0%;group C：（13.5±2.9） d,（1.32±0.29） mm,7.1%.Pleural effusion in three groups were compared,the time difference between the disappearance rate of pleural thickness,pleural adhesion was statistically significant（P 0.05）,pleural effusion patients in group C was significantly shorter in the dis appearance time of group A and B（P 0.05）,pleural thickness was significantly thinner than group A and B（P 0.05）,pleural adhesion rate was significantly lower than that of group A and B（P 0.05）.The incidence of adverse reactions among 3 groups was not significantly different（P 0.05）.Conclusion Intrapleural Urokinase combined with Dexamethasone is one of the most effective regimen for the treatment of tuberculous pleurisy,which is worthy of clinical ap plication and promotion.
出处
《中国医药导报》
CAS
2013年第15期104-105,108,共3页
China Medical Herald
基金
国家自然科学基金资助项目(编号81071318)
关键词
胸腔
尿激酶
地塞米松
结核性胸膜炎
Thoracic cavity
Urokinase
Dexamethasone
Tuberculous pleurisy
